Ideaya Biosciences announced that it intends to offer and sell up to $200M of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering. J.P. Morgan, Goldman Sachs & Co., Jefferies and RBC Capital Markets are acting as joint book-running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target raised to $62 from $55 at BTIG
- Ideaya Biosciences price target raised to $60 from $53 at Oppenheimer
- Ideaya’s IDE397 monotherapy data bode well for combo strategies, says Stifel
- Domino’s Pizza upgraded, Bumble downgraded: Wall Street’s top analyst calls
- Ideaya Biosciences initiated with an Outperform at Mizuho